This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Suma Krishnan spent decades working for other people before building a $4 billion biotech company based on her own inventions. Today, one of her FDA-approved drugs holds potential solutions for rare genetic diseases. #ForbesOver50 (Photo: Jamel Toppin) https://t.co/Os6v3SPdXa https://t.co/Lpmw0rw0o3 ...

Key Takeaways PRGO posted Q2 EPS of $0.57, up 7.5% but below estimates; sales dropped 0.9% to $1.06B.Sales fell due to exited businesses and weak segments, despite gains from currency tailwinds.PRGO cut 2025 sales view, citing infant formula and demand headwinds; EPS guidance remains intact.Perrigo (PRGO) reported adjusted earnings of 57 cents per share in the second quarter of 2025, missing the Zacks Consensus Estimate of 59 cents. The reported figure increased 7.5% year over year, primarily driven by lowe ...

Novartis is weighing a takeover of rare disease-focused biotech firm Avidity Biosciences in a bid to boost its drug pipeline, according to the Financial Times https://t.co/2xeZX2HC4g ...

Royalty Pharma (RPRX) Q2 2025 Earnings Call August 06, 2025 08:00 AM ET Company ParticipantsGeorge Grofik - Head - IR & CommunicationsPablo Legorreta - Founder, Chairman of the Board & CEOMarshall Urist - Head - Research & InvestmentsTerrance Coyne - Executive VP & CFOChris Schott - Managing DirectorUmer Raffat - Senior Managing DirectorMichael Nedelcovych - Director - Equity ResearchAshwani Verma - Executive Director - SMID Biotech & BiopharmaGeoff Meacham - Managing DirectorConference Call ParticipantsTer ...

Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the second quarter 2025 financial results and provide a business update on August 13, 2025, after the close of the market. The announcement ...

Core Points - The U.S. FDA has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for relapsed/refractory mantle cell lymphoma [1][2] - RMAT designation aims to accelerate the development and review of promising cell and gene therapies for serious conditions, with GLPG5101 showing preliminary clinical evidence of potential effectiveness [2][3] - Clinical data from the ATALANTA-1 study supports the RMAT designation, demonstrating high objective and complete response rates with a manageable safety profile [3][4] Company Overview - Galapagos is a biotechnology company focused on transforming patient outcomes through innovative science and technology, with operations in Europe, the U.S., and Asia [9] - The company is dedicated to addressing high unmet medical needs and has developed a decentralized cell therapy manufacturing platform to enhance patient experience and treatment delivery [8][9] Study Details - The ATALANTA-1 study is evaluating the safety and efficacy of GLPG5101 in patients with various hematological malignancies, with a primary objective to assess safety and determine recommended dosing [6] - The study includes multiple dose levels and aims to evaluate the Objective Response Rate (ORR) and other secondary endpoints, with patients being followed for 24 months [6] RMAT Designation Benefits - The RMAT designation allows for increased FDA guidance, more frequent interactions, eligibility for accelerated approval, and early discussions on study endpoints, facilitating faster development timelines [4]

China Healthcare Still in earning innings: Insights from China vs. Global innovative drug out-licensing deals The Hang Seng Healthcare Index has surged over 75% YTD, compared to an approximate 23% increase in the broader Hang Seng Index. This notable performance is driven by China's innovative drug out-licensing activities, which have emerged as a key catalyst behind sector-wide growth and sustained investor interest. In this report, we take a fresh approach to address key unanswered questions regarding Chi ...

SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2025. “We delivered an outstanding second quarter, achieving profitability in our MRD business with accelerating top- and bottom-line growth,” said Chad Robins, c ...

BioNTech SE BNTX reported a narrower loss for the second quarter on Monday.The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.The COVID-19 vaccine maker reported sales of $295.69 million (260.8 million euros), compared to 128.7 million euros a year ago, beating the consensus of $147.90 million.BioNTech reaffirmed its fiscal year 2025 guidance of 1.7 billion-2.2 billion ...